Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification

January 30, 2011 By Bio-Medicine.Org

CHADDS FORD, Pa., Jan. 31, 2011 /PRNewswire/ — Endo
Pharmaceuticals (Nasdaq:
ENDP
) announced today that its partners, Teikoku Seiyaku Co.,
Ltd. and Teikoku Pharma USA, Inc.,  have received a Paragraph
IV Certification Notice from Mylan Technologies Inc. advising of
the filing of an Abbreviated New Drug Application (ANDA) for a
generic version of LIDODERM® (lidocaine topical patch 5%).

The company is currently reviewing the details of this notice
from Mylan. Endo intends to vigorously defend LIDODERM’s
intellectual property rights and will pursue all available legal
and regulatory pathways in defense of LIDODERM.

The Paragraph IV certification notice refers to U.S. Patent Nos.
5,741,510 and 5,827,529, which cover the formulation of LIDODERM, a
topical patch to relieve the pain of postherpetic neuralgia
launched in 1999. These patents are listed in the U.S. Food and
Drug Administration’s (FDA) Orange Book and expire in March 2014
and October 2015, respectively.

Citizen Petition

With respect to Endo’s regulatory approach, the company
submitted a Citizen Petition in 2006 in reaction to a proposal by
FDA’s Office of Generic Drugs that would diverge from applicable
regulations and standards of practice regarding bioequivalence. The
company is requesting that the agency reconsider its departure from
its longstanding general rule of requiring clinical endpoint
bioequivalence studies for locally acting topical generic drug
products, including those that reference LIDODERM. To ensure the
safe and effective equivalence of any generic version to LIDODERM,
which acts locally in the skin, Endo believes that FDA must return
to its established standard of clinical endpoint bioequivalence
studies.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare
solutions company, focused on high-value branded products and
sp

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech